EST. 2023
NEW YORK · USA
US-REGISTERED
CPL-BIO · V2.0
COMMERCIAL ADVISORY → BIOPHARMA · LIFE SCIENCES

CPLBIOPHARMAINC.

美国注册 · 商业咨询 → 生物医药 / 生命科学US-Registered · Consulting → Biopharma / Life Sciences
CPL BIOPHARMA INC.
商业咨询起家 · 稳步拓展至早期医药项目评估From business advisory to early-stage biopharma evaluation

让每一分钱都花得值得。
物有所值 · 物超所值
Every dollar well spent.
Value delivered, value exceeded.

CPL BIOPHARMA INC. 前身为美国信息科技有限公司(American Information Technology Inc.),创立于 2023 年 9 月 22 日,2025 年更名为现名。公司专注市场调研、可行性分析与商业模式设计,帮助小微企业避开坑、降低试错成本,并将严谨的咨询能力延伸至生物医药与健康科技领域。

CPL BIOPHARMA INC., formerly American Information Technology Inc., was founded on Sept 22, 2023 and renamed in 2025. We specialize in market research, feasibility analysis and business-model design — helping small businesses avoid costly mistakes, now extending proven methods into biopharma and health tech.

2023 · 09 · 22美国注册成立 · 纽约Registered in the USA · New York
Biopharma laboratory
🔬 实验室级严谨 · 每一个结论都有证据支撑🔬 Lab-grade rigor · Every conclusion backed by evidence
✓ 可签 NDA✓ NDA available
Consulting meetingPharmaceutical research
中英双语交付Bilingual delivery
稳健 · 务实 · 价值优先 — 市场调研 · 可行性分析 · 商业模型 · 风险合规Prudent · Pragmatic · Value-first — Research · Feasibility · Business Models · Risk & Compliance

一家从证据出发的公司。A company that starts with evidence.

起点 · 2023ORIGIN · 2023

一家纽约咨询公司,
从小微企业开始。
A New York advisory firm,
starting with small business.

美国信息科技有限公司(American Information Technology Inc.)2023年9月22日注册成立,专注市场调研、可行性分析与商业模式设计,陪伴小微企业避开坑、降低试错成本。American Information Technology Inc. was registered on September 22, 2023, helping small businesses avoid pitfalls and cut trial-and-error cost through market research, feasibility analysis and business-model design.

沉淀 · 2023–2025METHOD · 2023–2025

方法,
在报告里长成。
Methods,
grown inside reports.

5份公开行业研究与企业个案,沉淀出可复用的方法:证据先行、花钱有纪律、结果可验证,坚持轻资产与透明运作。Five public industry studies and case reports forged a reusable method: evidence first, capital discipline, verifiable outcomes — asset-light and transparent throughout.

更名 · 2025NEW NAME · 2025

老能力,
新领域。
Proven methods,
a new arena.

2025年,公司更名为 CPL BIOPHARMA INC.,把同一套咨询能力带进医药早期项目评估:分阶段探索、从桌面研究起步,不承诺产品、审批与回报。In 2025 the firm became CPL BIOPHARMA INC., carrying the same advisory discipline into early-stage pharma evaluation: phased exploration starting from desk research — no promises on products, approvals or returns.

沿革本身,就是证据。The track record is the evidence.

01 → 02 · 从沿革到方法

看完我们从哪里来,接下来看我们怎么做事 — 同一套方法,用在每一个项目上。Where we come from → how we work — one method, applied to every project.

关于我们About us

CPL BIOPHARMA INC. — 先讲证据,再谈方案CPL BIOPHARMA INC. — Research before recommendations

CPL BIOPHARMA INC. 坚持“稳健、务实、价值优先”:任何项目开始前,先做独立、系统的市场调研;再结合你的资源、团队与成本结构,给出真正可执行的判断 — 帮你避免踩坑、减少试错、降低投入风险。

CPL BIOPHARMA INC. operates on “Prudent · Pragmatic · Value-first”: every engagement starts with independent, systematic market research, then maps your resources, team and cost structure into a truly executable plan — avoiding pitfalls, cutting trial-and-error and lowering investment risk.

🧭 方法之一 · 价值导向🧭 METHOD 01 · VALUE

价值导向Value-driven

不把篇幅花在漂亮话上;每一项工作都要回答“值不值得做、下一步怎么做”。We focus on two practical questions: is it worth doing, and what should happen next?

怎么做METHOD先明确决策问题,再选择恰当研究范围与分析深度。Define the decision first, then match the scope and depth of research.
看什么FOCUS投入、时间、风险敞口与潜在回报能否彼此匹配。Whether investment, timing, exposure and potential return align.
得到什么OUTPUT一份有优先级、可推进也可暂停的行动建议。A prioritized action view with clear advance-or-pause options.
🔍 方法之二 · 证据先行🔍 METHOD 02 · EVIDENCE

证据先行Evidence-first

观点可以讨论,关键判断必须有来源、逻辑与边界。Views can be discussed; critical conclusions need sources, logic and boundaries.

怎么做METHOD交叉核对公开资料、行业数据、客户访谈与竞争信息。Cross-check public sources, industry data, client input and competition.
看什么FOCUS市场容量、增长趋势、客户结构、竞争格局与行业风险。Sizing, trends, customer segments, competition and risk.
得到什么OUTPUT可追溯的判断依据,以及结论成立的前提条件。Traceable rationale and the assumptions behind each conclusion.
🛡️ 方法之三 · 稳健合规🛡️ METHOD 03 · PRUDENCE

稳健合规Prudent & compliant

不以乐观预测代替风险管理;重大投入前先识别约束与退出条件。No optimistic forecast replaces risk control; constraints and exits come first.

怎么做METHOD按阶段拆解假设、成本、责任边界与合规注意事项。Stage assumptions, cost, accountability and compliance considerations.
看什么FOCUS现金流压力、执行能力、信息披露与可逆性。Cash pressure, execution capacity, disclosure and reversibility.
得到什么OUTPUT风险清单、关键门槛与不满足条件时的止损建议。Risk list, decision gates and pause / stop guidance.
02 → 03 · 从方法到能力

方法有了,靠什么落地?是四个可以承接复杂问题的核心能力。Method is the principle — capability is what delivers it.

第一步 · 价值01 · VALUE

先算清价值,
再构建证据。
Value first.
Evidence next.

每一个复杂决定,都从一个更清晰的问题开始:这件事,值不值得做?Every complex decision begins with a clearer question: is it worth doing?

第二步 · 证据02 · EVIDENCE

让判断,
有来源、有边界。
Ground each decision
in traceable evidence.

结论不靠气势,而靠可以复核的依据、逻辑与前提。Conviction comes from evidence, logic and explicit assumptions — not volume.

第三步 · 系统03 · SYSTEM

把复杂性,
变成下一步。
Turn complexity
into the next move.

01价值判断Value assessment 02证据策略Evidence strategy 03执行设计Execution design
向前FORWARD

正在构建,
下一种可能。
Building toward
what comes next.

严谨的方法先行,未来的探索才有清晰的方向。A rigorous method gives future exploration a clear direction.

核心能力Capabilities

四个核心能力,只做算得清账的事Four core capabilities — only what we can underwrite

以下为公司长期沉淀的咨询能力,也是未来服务生物医药项目评估与孵化的基础方法论。

Our long-standing advisory capabilities — and the methodological foundation for future biopharma project evaluation and incubation.

5份公开研究 / 个案摘要
可直接查看方法与目录
Public research and case summaries
with visible methods and contents
4项核心能力
覆盖判断、规划、测算与风控
Core capabilities
from insight to planning and risk
CN / EN中英双语交付
正式合作前可签 NDA
Bilingual delivery
NDA available before engagement
📊

市场情报Market Intelligence

先看清牌桌,再决定是否上桌。

Read the table before sitting down.

  • 容量、趋势与需求驱动因素Market size, trends and demand drivers
  • 客户分层与竞争格局Customer segments and competitive landscape
  • 机会窗口与主要风险Opportunity windows and key risks
行业研究Industry report竞品地图Competitive map需求洞察Demand insight
🧭

可行性与战略Feasibility & Strategy

行不行,先把资源、路径与门槛算清。

Test resources, route and thresholds before committing.

  • 商业逻辑与定位匹配Business logic and positioning fit
  • 进入路径、收入模式与节奏Entry route, revenue model and pace
  • Go / No-Go 判断标准Go / no-go decision criteria
可行性分析Feasibility view策略路线图Strategy roadmap优先级建议Priorities
💰

财务与运营模型Financial & Operating Model

每一分钱的去向,都应对应一个经营假设。

Every dollar should map to an operating assumption.

  • 成本结构、现金压力与盈亏平衡Cost structure, cash pressure and breakeven
  • 收入逻辑与关键敏感变量Revenue logic and sensitive variables
  • 组织与流程的执行负荷Operating load across teams and processes
成本模型Cost model盈亏测算Breakeven view运营诊断Operations review
⚖️

风险与决策支持Risk & Decision Support

不确定并不可怕,边界不清才可怕。

Uncertainty is manageable; unclear boundaries are not.

  • 项目、运营与合规风险识别Project, operating and compliance risks
  • 关键假设与触发阈值Key assumptions and trigger thresholds
  • 停、改、进的决策依据Evidence to pause, adjust or advance
风险清单Risk register决策备忘Decision memo治理建议Governance view
查看完整 9 项服务模块 +Full 9-module list +
  • 市场调研与行业分析 — 容量、趋势、客户结构、竞争格局与风险Market research & industry analysis
  • 商业逻辑与可行性分析 — 结合资源与定位,避免误判Business logic & feasibility
  • 成本结构与运营压力分析 — 人力、租金、运营与获客成本Cost & operating-pressure analysis
  • 收入模式与盈利逻辑设计 — 确保商业模式可执行Revenue & profit-logic design
  • 企业发展规划咨询 — 目标、资源配置与增长节奏Growth & strategic planning
  • 公司治理结构咨询 — 架构、流程与制度建设Corporate governance
  • 运营与组织管理咨询 — 流程诊断与效率提升Operations & organization
  • 风险识别与合规建议 — 项目与运营风险规避Risk & compliance guidance
  • 问题诊断与解决方案设计 — 可落地的调整策略Diagnostics & solutions
03 → 04 · 从能力到理念

能力决定能做什么,理念决定怎么做 — 三句话,管住每一分钱。Capability defines what we can do — creed defines how we do it.

经营理念 · 承接能力Philosophy

稳健 · 务实 · 价值优先Prudent · Pragmatic · Value-first

减少试错、不走弯路 — 这是过去服务小微企业的初心,也是未来进入高投入、长周期、强监管的生物医药领域时,我们坚持审慎、分阶段探索的原因。

Fewer detours, lower trial costs — our original commitment to small businesses, and the reason we take a cautious, phased approach to high-investment, long-cycle, highly regulated biopharma.

理念之一 · 证据先行CREED 01 · EVIDENCE

证据先行Evidence First

先验证问题是否成立,再讨论方案是否漂亮。Confirm the question is real before polishing the answer.

原则RULE区分事实、推断与待验证假设。Separate facts, inferences and open assumptions.
动作ACTION记录来源、核对口径、标注数据边界。Log sources, align definitions, flag boundaries.
结果RESULT让结论能被复核,而非只能被相信。Make conclusions reviewable, not merely believable.
理念之二 · 花钱有纪律CREED 02 · DISCIPLINE

花钱有纪律Capital Discipline

每一次投入,都要对应一项待验证的关键假设。Every spend should test a material assumption.

原则RULE先小步验证,不以规模掩盖不确定性。Validate in small steps; never hide uncertainty with scale.
动作ACTION设预算上限、阶段门与下一笔资金条件。Set budget caps, stage gates and release conditions.
结果RESULT在可控成本内获得继续或停止的依据。Earn evidence to advance or stop at controlled cost.
理念之三 · 结果可验证CREED 03 · OUTCOMES

结果可验证Measurable Outcomes

交付不是“报告完成”,而是客户可以据此行动。Delivery means a client can act, not merely receive a report.

原则RULE把建议落到负责人、时间与判断标准。Anchor advice to owners, timing and decision criteria.
动作ACTION给出优先级、行动项、风险提示与复盘节点。Provide priorities, actions, risks and review points.
结果RESULT将复杂信息转化为可执行的下一步。Turn complex information into executable next steps.
04 → 05 · 从理念到实证

理念不是口号 — 下面 5 份报告,每一份都是上面的理念长出来的样子。Creed is not a slogan — the 5 reports below are what it looks like in practice.

研究能力实证Research

我们用报告证明方法论Proven methods, documented in reports

以下为公司近年完成的中英文行业调研与企业个案 — 点击「查看完整脱敏摘要」直接打开摘要页,点击「索取该样本」直接跳转联系表单(需求类型自动填好)。公开版已隐去客户真实名称与地址、人名;完整版可在正式咨询时索取(可签 NDA)。

Selected industry and case studies below — click “Full summary” to open the redacted summary page, or “Request sample” to jump to the contact form (inquiry pre-filled). Client names, addresses and personal names are removed in the public version. Full versions available upon formal engagement (NDA available).

01 · 行业研究01 · Industry Report

2025 纽约州餐饮行业 · 厨房日用品批发研究报告2025 NY Restaurant & Kitchenware Wholesale Report

市场容量 / 增长趋势 / 客户结构 / 竞争格局 / 风险全覆盖。Full coverage: sizing, trends, customers, competition and risks.

七章结构 · 2000+段正文 · 6个数据模型表7 chapters · 2000+ paragraphs · 6 data tables

Wholesale warehouse
02 · 行业研究02 · Industry Report

2025 纽约市美容院行业调研报告2025 NYC Beauty Salon Industry Report

门店模型、成本结构、获客与复购逻辑拆解。Store models, cost structure, acquisition and retention logic.

九大模块诊断 · 600+段正文Nine-module diagnosis · 600+ paragraphs

Beauty salon
03 · 行业研究03 · Industry Report

2025 纽约市食品进口行业调研报告2025 NYC Food Import Industry Report

供应链、合规与渠道三维分析,识别高风险环节。Supply chain, compliance and channel analysis with risk mapping.

五大区分区扫描 · 2000+段正文 · 七环节链条Five-borough scan · 2000+ paragraphs · 7-link chain

Food import containers
04 · 企业个案(已脱敏)04 · Case Study (Redacted)

纽约州餐饮耗材批发企业个案调研(代号 H·Wholesale)NY Foodservice Consumables Wholesaler — Case Study (Codename H·Wholesale)

企业级深度个案:业务诊断 + 可行性 + 发展路径。In-depth diagnostics, feasibility and growth roadmap.

12章完整版 · 1900+段正文 · 5个数据表Full 12 chapters · 1900+ paragraphs · 5 data tables

Wholesale business
05 · 企业个案(已脱敏)05 · Case Study (Redacted)

大纽约地区非银行信贷机构个案调研(代号 R·Capital,2025)Greater-NY Non-Bank Lender — Case Study (Codename R·Capital, 2025)

资本与治理视角的项目评估,兼顾商业与合规。Capital & governance review balancing business and compliance.

1200+段正文 · 注册核验与行业对标1200+ paragraphs · registration & benchmarking

Financial building
工作流程Process
🔍
01 调研01 Research

独立系统取证

Independent evidence

🧮
02 测算02 Modeling

成本·收入·风险

Costs · revenue · risks

🧩
03 设计03 Design

模式·路径·节奏

Model · path · pacing

📋
04 规划04 Planning

可执行方案

Executable plan

🤝
05 陪跑05 Support

调整·优化·复盘

Adjust · refine · review

05 → 06 · 从过去到未来

过去用报告证明方法,未来用同一套方法看新方向 — 不换逻辑,只换赛道。Proven in the past, applied to the future — same logic, new arena.

下一步,从证据出发。The next step starts with evidence.
未来方向Future

从商业咨询,到生物医药与生命科学From business advisory to biopharma & life sciences

CPL BIOPHARMA INC. 将在保留原有咨询能力的基础上,逐步将业务关注方向拓展至生物医药、生命科学、健康科技及相关产业服务 — 采取审慎、合规、分阶段的方式。

CPL BIOPHARMA INC. will build on proven advisory capabilities and gradually expand into biopharma, life sciences, health tech and related industry services — in a prudent, compliant, phased manner.

※ 以下均为探索方向,不代表现有产品、临床项目或监管批准。※ Exploratory directions only — not existing products, trials or approvals.

现在已交付 · 有报告为证Delivered · Evidenced

商业咨询:5 份报告,可查目录Advisory: 5 reports, checkable

  • 市场规模测算(如 32–36 亿美元内部模型估算区间,非官方统计)Market sizing (e.g. $3.2–3.6B internal modeling estimate, not official stats)
  • 成本 / 盈利结构拆解与 SOP 诊断Cost / profit breakdowns & SOP audits
  • Go / No-Go 决策依据与路线图Go / no-go basis & roadmaps
现在可接 · 老方法做新题Available now · Same methods

医药早期项目评估(咨询范畴)Early pharma evaluation (advisory)

  • 适应症规模与支付意愿桌面测算Desk sizing of indications & willingness-to-pay
  • 立项可行性过会材料与资金规划Feasibility packs & funding plans
  • 合规风险清单(非法律意见)Compliance risk lists (not legal advice)
未来探索 · 条件就绪才谈Exploratory · Conditional

研发 / 孵化:四个方向分阶段看R&D / incubation: phased

  • 需团队、资金、合作与合规四项就绪Requires team, funding, partners, compliance
  • 任何阶段设退出标准、可停Exit criteria at every gate
  • 不承诺产品、审批与回报No promise on products, approvals, returns
当前所处:阶段一 · 桌面研究(跟踪方向、积累判断,不投钱)Current phase: Phase 1 · Desk research (track & learn, no capital at risk)
👇 四个探索方向,点击切换 — 每个方向只做能算清账的部分👇 Four exploratory tracks — click to switch; each limited to what we can underwrite

精准医疗 — 先分层,再谈投入Precision medicine — segment first, fund later

延续咨询的“客户分层”功底:先把人群、适应症、支付意愿算清楚,再谈投不投。

Our segmentation discipline applied to populations and indications: size the pool and the willingness to pay before committing a dollar.

  • 适应症与人群规模、支付意愿测算Indication sizing and willingness-to-pay analysis
  • 竞品格局与差异化窗口判断Competitive landscape and differentiation windows
  • 进入 / 放弃的量化门槛,花钱前先写好Go / no-go thresholds, written before spending
Precision medicine

细胞与免疫 — 长周期,先算资金账Cell & immuno — fund the long cycle first

细胞技术与肿瘤免疫周期长、投入大:先拆里程碑、再排融资节奏,绝不一次 All-in。

Long-cycle, capital-heavy programs get milestone-based budgets and financing rhythms — never all-in upfront.

  • 按里程碑拆解成本与风险敞口Milestone-based cost and exposure breakdown
  • 融资节奏与现金流安全垫Financing cadence and cash cushions
  • 每阶段退出标准,事先约定Pre-agreed exit criteria at every gate
Cell therapy lab

人工智能辅助研发 — 工具提效,判断守规AI-assisted R&D — tools for speed, evidence for calls

人工智能负责初筛与提效,关键结论必须经人工证据复核与合规审查。

AI handles triage and acceleration; critical conclusions pass human evidence review and compliance checks.

  • 文献、靶点、数据三类初筛Literature, target and data triage
  • 研发流程提效降本测算Measurable efficiency and cost gains
  • 不夸大、不承诺疗效,结论可复核No hype on efficacy; every conclusion reviewable
AI research

项目孵化 — 小步验证,分段给钱Incubation — prove small, fund in stages

照搬服务小微企业的“小步快跑”:可行性过会 → 小规模验证 → 条件具备再放大。

Our small-business playbook: feasibility gate, small-scale validation, scale-up only when earned.

  • 立项可行性门槛与过会标准Feasibility thresholds and review standards
  • 小规模验证指标与周期Small-scale validation metrics and timelines
  • 放大条件与止损线Scale-up conditions and stop-loss lines
Incubation

🔗 凭什么做医药:老能力 → 新场景🔗 Why us: proven skills, new arena

  • 市场调研 → 适应症规模与支付意愿测算Market research → indication sizing & willingness-to-pay
  • 可行性分析 → 医药立项过会依据Feasibility analysis → project approval basis
  • 成本收入模型 → 研发资金与融资规划Cost-revenue models → R&D funding plans
  • 治理与风控 → 合规体系与信息披露Governance & risk → compliance and disclosure

🧭 怎么推进:三阶段路线🧭 How we advance: three phases

  • 阶段一 · 桌面研究:跟踪方向、积累判断,不投钱Phase 1 · Desk research: track and learn, no capital at risk
  • 阶段二 · 小步验证:小规模试点,验证假设与成本Phase 2 · Small pilots to test theses and costs
  • 阶段三 · 条件放大:团队、资金、合规就绪后再谈规模Phase 3 · Scale only when team, funding and compliance are ready
  • 全程设退出标准,任何阶段都可以停Exit criteria throughout; we can stop at any gate
⚠️ 重要说明:上述方向为公司拟关注和探索的领域,不代表已形成成熟产品、临床项目、商业化收入或监管批准。公司尚未对任何产品、技术、审批、融资或回报作出保证。本页关于未来的表述属前瞻性陈述,实际结果可能因市场、资金、团队、合作与监管等因素产生重大差异,不构成证券发行、投资建议或收益承诺。⚠️ Disclosure: areas above are exploratory only and do not imply mature products, clinical programs, revenue or approvals. No guarantee on products, technology, approvals, financing or returns. Forward-looking statements subject to material risks. Nothing herein is an offer or investment advice.
06 → 07 · 从方向到人

方向再大,也要有人扛 — 下面是为这条路负责的人。Directions need owners — the people accountable for this path.

董事会 · 执行方向的人Board of Directors

资本与产业双线带队的董事会A board spanning capital markets and industry

董事会成员的公开履历覆盖纳斯达克上市公司治理与生物制药研发体系,代表性资本市场案例可参考 spacglobal.com。

The board's public track record spans Nasdaq-listed company governance and biopharma R&D; representative capital-markets cases are showcased at spacglobal.com.

Qi Gong
董事长Chairwoman

Qi GongQi Gong

纳斯达克 Quartzsea(QSEA)董事长兼首席执行官、首席财务官;QuasarEdge(QRED)董事长兼首席执行官、首席财务官;Yotta(YOTA)、Quetta(QETA)、Quantumsphere(QUMS)独立董事。美国华尔街上市融资集团及美国信息科技创始人,合肥工业大学毕业,总统志愿服务奖得主。Chairwoman, CEO & CFO of Nasdaq-listed Quartzsea (QSEA); Chairwoman, CEO & CFO of QuasarEdge (QRED); independent director of Yotta (YOTA), Quetta (QETA) and Quantumsphere (QUMS). Founder of the American Wall Street Listed Group and American Information Technology Inc.; Hefei University of Technology graduate; recipient of the President's Volunteer Service Award.

Pen Lan
董事Director

Pen LanPen Lan

董事会成员。详细简介即将公布。Member of the board. Full bio coming soon.

Keejong Chang
董事Director

Keejong ChangKeejong Chang

可蓝赛生物医药(上海)董事长兼首席技术官;25年以上生物制药研发与产业化经验;加州大学河滨分校生物化学博士;3项美国专利、1项欧洲专利,发表学术论文29篇以上。Chairman & CTO of Keycell Lines Biopharmaceutical (Shanghai); 25+ years across drug discovery, biologics and cell/gene platforms; Ph.D. in Biochemistry, UC Riverside; inventor on 3 U.S. and 1 European patent; 29+ scientific publications.

07 → 联系 · 从人到行动

故事讲完了,验证可以开始了 — 留下你的问题,我们用证据回答。The story ends here — verification starts with your question.

联系我们 · 下一步行动Contact

欢迎垂询,预约专业咨询Contact Us for a Professional Consultation

敬请留下您的项目需求,我们会尽快予以回复。正式合作前可签署保密协议(NDA),以保障双方信息安全。

Please share your project requirements; we will respond promptly. An NDA is available prior to formal engagement to protect your confidential information.

期待与您进一步探讨合作可能We Look Forward to Discussing Your Project

无论是小微企业经营决策,还是医药早期项目评估,我们将基于数据与证据,为您提供客观、严谨的初步分析与专业建议。

From small-business decisions to early-stage pharmaceutical evaluation, we provide objective, evidence-based preliminary analysis and professional guidance.

✍️
01 留下需求01 Tell us your needs

简单描述行业与问题

Briefly describe your industry and needs

🔍
02 初步评估02 Preliminary view

基于数据与证据的客观判断

Objective, evidence-based assessment

🤝
03 NDA + 正式合作03 NDA + engagement

签署保密协议后交付完整方案

Full deliverables after NDA

CPL BIOPHARMA INC.

服务时间:周一–周五 9:00–18:00 (ET) · 中英双语服务Hours: Mon–Fri 9:00–18:00 (ET) · Bilingual support

⤢ 点击放大⤢ Enlarge